Daughter slams NHS after dad, 86, denied end-of-life care
The ICB's decision to slash spending has been made to meet nationally-set government targets - but the proposed cuts to continuing healthcare (CHC) plans have drawn heavy criticism from council leaders and residents alike.
Kathlyn Gadd, 63, says she is worried that the cuts will have a profound impact on patient welfare going forward. Her 86-year-old father, Geoffrey Foddy, was recently denied end-of-life care - shortly before the cuts were announced.
READ MORE: 30 throwback photos from Stoke-on-Trent Big Night Out - recognise anyone?
READ MORE: New plans for massive North Staffordshire solar farm two councils tried to stop
She told StokeonTrentLive: 'My dad was admitted to Vascular Ward at the Royal Stoke University Hospital with a clot that was cutting off the blood supply to his leg. They couldn't operate or offer an amputation because he's frail and old.
'Essentially, it was a case where they couldn't do anything for him. So they said they'd send him home with end-of-life palliative care. His discharge letter said he had weeks to live.'
Despite being told he would given palliative care on June 13, 2025, Geoffrey and his family were left shocked after the hospital discharge team quickly overturned the decision on June 17.
Kathlyn explained: 'They basically went into my dad's room while he was on his own and told him that he didn't qualify for palliative care because he wasn't going to die fast enough. Apparently it was because they thought he'd live beyond two weeks. They also said the medication he was on was deferring the gangrene.
'This was the first time my dad fully realised he was terminal. He was very distressed. The staff on the ward were horrified with the decision. One of the nurses was in tears with him. We appealed the decision twice while he was on the ward, but we were unsuccessful. Some doctors we spoke to said this was a recurring issue.
'When we asked them what is their kind of definition for when palliative care should be prescribed, their response was that it should be given when a patient is no longer eating or drinking. So you're talking literal days before they die.'
Kathlyn believes the situation was handled in the "most inhumane and unempathetic manner possible".
'I had two reactions to this news,' she said. 'I was extremely upset with the decision and I was extremely angry with how they chose to tell him. The way they just walked in and announced it without any family there.
'When you're facing losing the prospect of losing a family member, you're already dealing with an awful lot of things. And this lack of compassion, this treatment that you're just a line on a spreadsheet that can be cut, is just completely lacking in humanity.
'It's just callous. And now these cuts are essentially going to mean that more people who would qualify for palliative care aren't qualifying. And it means that people are going to have to fund the costs of care themselves, despite being entitled to receive support. It's just another burden on people in the community.'
The Staffordshire and Stoke-on-Trent ICB said it is aware of Kathlyn's concerns.
But they have insisted that Geoffrey has been appropriately assessed on multiple occasions, and that he does not meet the nationally-set criteria for the End of Life Home Care Pathway.
An ICB spokesperson said: 'The Palliative Care Coordination Centre continues to monitor the patient via community nurses who are continuing to visit the patient daily to provide at home care and support.
'Should any deterioration in the patient's condition be observed another referral will be made immediately. We would like to issue our best wishes to the family.'
Get daily headlines and breaking news emailed to you - it's FREE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Girl who died in hospital ‘should have been watched at all times', inquest hears
A teenager who died after an agency worker with false identity papers left her unsupervised at a children's mental health hospital should have been kept within eyesight at all times, an inquest has heard. Ruth Szymankiewicz was being treated for an eating disorder at Huntercombe Hospital in Berkshire and had been placed under strict one-to-one observation when on February 12 2022 she was able to shut herself in her bedroom alone for 15 minutes, a jury inquest held at Buckinghamshire Coroner's Court heard on Tuesday. The 14-year-old girl self-harmed and died two days later at John Radcliffe Hospital in Oxford. It later emerged the member of staff responsible for watching Ruth at the hospital's psychiatric intensive care unit – a man then known as Ebo Acheampong – had been using false identity documents and was hired under a false name. The teenager was last captured on CCTV walking out of the ward's day room 'completely on her own' before going straight to her bedroom and closing the door behind her, coroner Ian Wade KC told the hearing. Jurors were shown the footage in which 15 minutes pass before a nurse opens the door, then covers her mouth in what appears to be an expression of shock. Ellesha Brannigan, who worked as a clinical team leader on the ward, told the court on Tuesday she ran to Ruth's bedroom after the alarm was raised and found the teenage girl lying unconscious. 'She was just still,' Ms Brannigan said, adding the teenage girl was not breathing and staff initiated chest compressions in an attempt to revive her. About a week prior, Ruth's care plan had been escalated to 'level three observation' after a similar self-harming incident, Ms Brannigan told the court. 'Level three observation is within eyesight at all times,' she told the hearing. Staff members would take turns watching Ruth for 60 minutes at a time, the inquest heard. Ms Brannigan further told the inquest 'level two observation' would have still required a member of staff check on the patient 'every five or 10 minutes'. Asked by the coroner if there were circumstances in which a member of staff responsible for a level three observation could take their eyes off the patient, she replied: 'No. 'If they (the patient) are prescribed level three observation, you must comply with what is prescribed.' The coroner previously said Mr Acheampong will not be giving evidence at the inquest as he fled the UK for Ghana shortly after Ruth's death. The inquest continues.
Medscape
an hour ago
- Medscape
NICE Urges Ongoing Support After Obesity Treatment
The National Institute for Health and Care Excellence (NICE) has released updated guidance recommending that healthcare providers offer structured, ongoing support to patients after they complete obesity treatment or stop taking weight-loss medications. This includes regular follow-up care, tailored action plans, and social support to help patients maintain their weight loss and avoid regaining weight. New Drugs Raise Need for Long-Term Support The new quality standard comes as weight-loss medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are being introduced on the NHS. An estimated 240,000 people are set to be offered tirzepatide over the next 3 years. The update addresses a critical gap in current care, noting that many people regain weight after treatment if they lack adequate support, with consequences for both physical and mental health. In England, 29% of adults are living with obesity and 64% of adults are classified as overweight or obese. Obesity-related illnesses are estimated to cost the NHS £11.4 billion a year and have a wider economic impact of £74.3 billion. Ensuring Continuity of Care The guidance stresses that weight management is a long-term process, not a one-time fix. It recommends that healthcare providers ensure continuity of care by monitoring patients for at least 12 months and offering tailored support to help maintain weight loss. This may include NHS Better Health resources and strategies for habit change, as well as practical adjustments at home or at work. The quality standard advocates for a shift from short-term interventions to strategies that foster lasting behavioural changes. It highlights the importance of self-monitoring and connecting patients with broader support networks, such as online communities, family-led initiatives, and local programmes. Guidance Implementation Professor Jonathan Benger, deputy chief executive of NICE, noted that weight management 'doesn't end when medication stops or when someone completes a behavioural programme,' adding that 'people need structured support to maintain the positive changes they've made.' The new guidance replaces three previous standards and reflects the most up-to-date strategies for tackling obesity through the healthcare system. Healthcare services are advised to begin implementing the standard immediately, with resource impact guidance available to assist in local adaptation.
Yahoo
an hour ago
- Yahoo
Experts reveal potential unintended side effect of Ozempic – and whether we should worry
The use of weight-loss jabs in the UK has skyrocketed, with an estimated 1.5 million people using them. Yet drugs like Ozempic and Wegovy don't just help people lose fat, but potentially muscle too, new research has suggested. A study that tested weight loss jabs on mice found that although muscle mass changes less than expected, muscles still get weaker and tissues like the liver also shrink. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. The medications, known as semaglutides, predominantly treat diabetes but are also available on the NHS or via private providers to help adults with a high body mass index (BMI). For example, although Ozempic is used for type 2 diabetes, it is sometimes prescribed off-label as a weight-loss drug. The results of the study, published in the journal Cell Metabolism, revealed Ozempic-induced weight loss decreased muscle mass by about 10 per cent. Most of this lost weight wasn't from skeletal muscles, which surround bones and joints, but instead from other tissues like the liver, which shrank by nearly half. However, because the Ozempic was tested on mice, researchers emphasise that more research is needed to determine whether similar changes to organ size occur in humans and whether those changes come with any risks. 'Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss,' said Dr Ran Hee Choi, research instructor in nutrition and integrative physiology at the University of Utah college of health, and co-first author on the study. In both mice and humans, weight gain and loss can affect the size of organs like the liver without affecting their function. 'It's unlikely that the observed lean mass loss represents a serious adverse effect,' added Dr Takuya Karasawa, another co-first author on the study. Researchers found some skeletal muscles did shrink by about 6 per cent as the mice lost weight, but not enough to explain the overall muscle loss. However, when someone gains fat, they also tend to gain skeletal muscle. Study authors explain this is because the body needs to work harder to move around. As a result, losing extra fat can lead to a loss of muscle, which will not affect the person's overall quality of life. Researchers also tested the amount of force the mice's muscles exerted and found that some muscle strength decreased as the mice lost weight, even when the size of the muscle stayed roughly the same. This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility. 'The loss of physical function is a strong predictor of not just quality of life but longevity,' added Dr Katsu Funai, professor of nutrition at the University of Utah and the senior author on the study. Dr Funai concluded that further clinical trials of weight loss jabs should check for changes in muscle strength. A spokesperson for Novo Nordisk, which makes Ozempic, said: 'In clinical trial for Wegovy or Ozempic we did not specifically study the medicine's impact on muscle mass. In a sub-study of 140 patients with a BMI of 40 or less, analysis suggested that treatment with Wegovy was accompanied by reductions in both fat and lean body mass, with a greater reduction in fat mass than lean body mass. 'We recommend that any patients experiencing side effects while taking Wegovy or Ozempic contact their healthcare provider.'
